Watch 4:29
Fauci tells Congress he’s ‘cautiously optimistic’ about vaccine this year
The coronavirus continues to spread across the United States, bringing with it immense economic damage. So far, Congress has been unable to deliver another pandemic relief measure, prompting House Democrats to cancel a planned August recess. But there were signs…
WATCH: Dr. Fauci says thousands signing up for virus trials
Dr. Anthony Fauci testified says 250,000 people have registered on a National Institutes of Heath website to take part in experimental vaccine trials.
U.S. sinks another $2.1 billion into a potential vaccine
Pharma giants GlaxoSmithKline and Sanofi Pasteur have announced they will supply 100 million doses of its experimental COVID-19 vaccine to the United States as drugmakers scramble to develop drugs to stem the pandemic.
WATCH: Trump speaks at drug-making plant to tout COVID-19 vaccine development
“I heard very positive things,” Trump said, when asked about the timetable for bringing a vaccine to market, “but by the end of the year we think we’re in very good shape to be doing that.”…
The world’s biggest COVID-19 vaccine study got underway Monday with the first of 30,000 planned volunteers helping to test shots created by the U.S. government.
The question of when a COVID-19 vaccine might be available is perhaps the most pressing in the world. There have been a number of recent headlines on this front, including early but encouraging results from trials. And on Wednesday, the…
he Trump administration will pay Pfizer nearly $2 billion for a December delivery of 100 million doses of a COVID-19 vaccine the pharmaceutical company is developing, Health and Human Services Secretary Alex Azar announced Wednesday.
The House Oversight and Investigations Subcommittee will hold a hearing July 21 on the current state of research, development, and manufacturing of potential vaccines for COVID-19.
In research published Monday in the journal Lancet, scientists said that they found their experimental COVID-19 vaccine produced a dual immune response in people aged 18 to 55 that lasted at least two months after they were immunized.
Additional Support Provided By:
